Akero Therapeutics, Inc.
Akero Therapeutics, Inc. (AKRO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
akro · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Akero Therapeutics, Inc. (AKRO) measures how much investors pay for each dollar of the company's trailing earnings. AKRO's current PE ratio of N/A is calculated by dividing its stock price of $54.65 by its TTM earnings per share of -$3.57.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2017 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Akero Therapeutics, Inc.You AKRO | $4.5B | N/A | — | -$3.57 |
 ACADIA Pharmaceuticals Inc. ACAD | $3.7B | 11.57x | — | $2.31 |
 Arcellx, Inc. ACLX | $6.7B | N/A | — | -$4.07 |
 Centessa Pharmaceuticals plc CNTA | $6.1B | N/A | — | -$1.46 |
 Crinetics Pharmaceuticals, Inc. CRNX | $3.5B | N/A | — | -$4.95 |
 Immunovant, Inc. IMVT | $6.3B | N/A | — | -$2.77 |
 Kymera Therapeutics, Inc. KYMR | $6.1B | N/A | — | -$3.69 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-3.75 | — | |
2023-12-31 FY2023 | — | $-2.89 | — | |
2022-12-31 FY2022 | — | $-2.87 | — | |
2021-12-31 FY2021 | — | $-2.89 | — | |
2020-12-31 FY2020 | — | $-2.52 | — | |
2019-12-31 FY2019 | — | $-2.90 | — | |
2018-12-31 FY2018 | — | $-3.85 | — | |
2017-12-31 FY2017 | — | $-0.16 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Akero Therapeutics, Inc. (AKRO) measures how much investors pay for each dollar of the company's trailing earnings. AKRO's current PE ratio of N/A is calculated by dividing its stock price of $54.65 by its TTM earnings per share of -$3.57.
Frequently asked questions
AKRO pe ratio · 6 questionsAKRO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $54.65 and TTM EPS of -$3.57. Data sourced from Financial Modeling Prep via AKRO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Akero Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08